Neoadjuvant Treatment for Surgically Resectable Metastatic Colorectal Cancer

January 16, 2016
Marwan Al-Hajeili, MD

,
John L. Marshall, MD

,
Brandon G. Smaglo, MD

Here, we review the studies that have explored different treatment regimens, therapeutic sequencing, and biologic inclusions for the treatment of these patients, with neoadjuvant intent. We also describe how we have established our own treatment paradigm for the management of potentially curable metastatic colorectal cancer.

The curative surgical resection of metastatic disease in patients with stage IV colorectal cancer with a limited tumor burden is standard of care. However, the role for neoadjuvant medical therapy and the ideal composition of that therapy are not established. Several neoadjuvant medical therapies, including standard advanced colorectal cancer chemotherapy regimens-such as folinic acid, fluorouracil (5-FU), and oxaliplatin (FOLFOX); folinic acid, 5-FU, and irinotecan (FOLFIRI); and folinic acid, 5-FU, oxaliplatin, and irinotecan (FOLFOXIRI)-have been evaluated, as has the addition of the biologic agents bevacizumab, panitumumab, and cetuximab. Those patients who are immediate surgical candidates do not seem to benefit from a neoadjuvant medical approach and should proceed directly to surgical resection. Those patients who are not surgical candidates at presentation can in some instances achieve a conversion of disease to a curable state with systemic therapy. Here, we review the studies that have explored different treatment regimens, therapeutic sequencing, and biologic inclusions for the treatment of these patients, with neoadjuvant intent. We also describe how we have established our own treatment paradigm for the management of potentially curable metastatic colorectal cancer.

Overview

In the United States, colorectal cancer was predicted to have the fourth highest rate of incidence of new diagnoses among all cancers in 2015, with over 130,000 new cases expected.[1,2] Twenty percent of patients with newly diagnosed colorectal cancers present with metastatic disease. The average 5-year survival for metastatic colorectal cancer is 12.9%.[2] Surgical resection is the only potentially curative option for patients with this disease. However, there are limitations to its use, since less than 15% of patients with metastatic colorectal cancer have disease that is considered resectable at diagnosis,[3] and the failure rate remains high.[4] Thus, a number of studies have evaluated the role of preoperative medical therapy to improve metastasectomy outcomes, both as neoadjuvant therapy for resectable metastatic disease and as a method for converting unresectable metastatic disease into resectable disease.[5] These preoperative medical approaches could also have implications for patients who have localized disease, since up to 20% of these patients will go on to develop metastatic recurrent disease within 5 years of their initial diagnosis.[2,6]

The most common site for distant metastases from colorectal cancer is the liver.[7] Among all patients with hepatic metastases, potential resection is limited to about 15% to 20% upon presentation. To improve outcomes in patients with unresectable liver metastases, systemic treatment has been evaluated as a method for converting unresectable to resectable disease.[5] Certain clinicopathologic features have been identified to suggest which patients could benefit from hepatic metastasectomy. In the past, the contraindications for hepatic metastasectomy were the presence of four or more metastases within the liver, the presence of extrahepatic metastases, the presence of large hepatic metastases, or the inability to obtain more than 1-cm negative margins at hepatic metastasectomy.[8] However, because of the inconsistent and conflicting prognostic value of these clinicopathologic features, the paradigm of resectability has changed. The new paradigm considers the ability to achieve an R0 resection upon metastasectomy as the most relevant indication for offering this intervention. The limitations to this approach are preserving adequate functional tissue after surgery, biliary drainage, and vascular inflow and outflow structure, as well as the need to spare at least two adjacent segments or 20% or more of the liver tissue.[8]

Of all patients with metastatic colorectal cancer, up to 2.3% have lung metastases at presentation, and up to 22.4% have lung metastases with disease recurrence.[7] There are no defined criteria for resectability of lung metastases. Certain prognostic factors should be addressed carefully before surgery because they suggest an association with higher rates of recurrence. These factors include bilateral lung metastases or more than six lung lesions. Patients who have involvement of other organ sites are generally considered to be at high risk for recurrence as well.[8] However, surgery could be attempted if, after multidisciplinary discussion, R0 resection is deemed possible with acceptable morbidity and mortality.

Preoperative Treatment Approach

Potential advantages of preoperative therapy for liver or other metastases from colorectal cancer are the earlier treatment of micrometastases, assessment of tumor response to chemotherapy, avoidance of surgery in patients who have early disease progression, and conversion of unresectable to resectable tumors. The drawback to a preoperative approach is potential toxicity from chemotherapy; for example, liver steatohepatitis has been reported at a rate of 4% to 11% and sinusoidal liver injury at a rate of 26% to 42%.[9] A further disadvantage is interval disease worsening that could exclude surgery as an option.[10] The ultimate goal of this preoperative treatment is of course cure, and different factors have been evaluated as surrogate measures of outcome to determine the benefit of such treatment in achieving a cure. John et al showed that 5-year survival in patients with R0 resection was 46.7%, compared with 14.6% in patients with R1 resection (P < .001).[11] Similarly, Tan et al reported that 10-year disease-specific survival was 68% for liver metastasis resection in colorectal cancer patients.[12] Therefore, if a different treatment approach, such as neoadjuvant therapy, can increase rates of R0 resection, it may in turn lead to higher rates of cure.

Multiple chemotherapy agents and antibody therapies have demonstrated effectiveness in the management of patients with metastatic colorectal cancer. Meanwhile, a limited number of agents (fluoropyrimidine with or without oxaliplatin) have demonstrated effectiveness in the adjuvant setting. Many of these regimens have been explored for their preoperative impact in the treatment of patients with both resectable and unresectable disease. The studies discussed here are summarized and categorized by these two different intentions in Tables 1 and 2.

FOLFOX and CAPEOX

Doublet chemotherapy regimens using a fluoropyrimidine paired with oxaliplatin have an established curative role for the adjuvant management of patients with stage III colorectal cancers, and thus serve as a natural choice of therapy for exploration in the preoperative management of potentially curable metastatic disease. In a phase II trial, Alberts et al reported outcomes of the use of folinic acid, fluorouracil (5-FU), and oxaliplatin (FOLFOX) as a conversion therapy in 42 patients with liver-only metastases that were deemed unresectable due to major liver vasculature involvement or more diffuse liver metastases.

The median number of treatment cycles was 10; the overall response rate (ORR) was 60% (95% confidence interval [CI], 46%–75%). Of the 17 patients who underwent surgery, 14 (33% of the total enrollment) had complete resection (R0). The overall median time to disease recurrence for all surgical patients who had a relapse was 19 months, and the median 3-year overall survival (OS) was 71%.[13] Adam et al retrospectively evaluated conversion chemotherapy using 5-FU and oxaliplatin to treat 701 patients with metastatic colorectal cancer deemed to have unresectable disease; chemotherapy dose schedule was modified and optimized during the study period (1988–1996), in keeping with then-current standards. Patients received neoadjuvant therapy for a mean of 10.6 months. The conversion rate to resection was 13.6%, and 5-year OS after resection was 34%. Six patients had a pathologic complete response; of these patients, the 5-year OS was 83%, and 50% had no evidence of disease at 5-year follow-up.[14] Coskun et al retrospectively reviewed capecitabine and oxaliplatin (CAPEOX) as a conversion therapy in 35 patients with unresectable liver metastases. The median number of treatment cycles was 4 (range, 2–9). The ORR was 37.2%; however, 20% of the patients were converted to surgically resectable disease based on imaging results. Of the five patients who had surgery, four (11.4%) had an R0 resection.[15]

Neoadjuvant therapy using a fluoropyrimidine/oxaliplatin doublet has also been explored in patients with metastatic disease that is deemed resectable upon presentation. These investigations have only been early-phase studies; direct comparisons with upfront surgery have not been carried out. Wein et al used FOLFOX in the neoadjuvant setting for metastatic colorectal cancer patients who were considered to have resectable liver metastases upon presentation. Twenty patients were enrolled in this phase II trial, and all underwent resection, with 80% achieving an R0 resection outcome. Pathologic complete response was observed in 18.7% of patients.[16] The 2-year disease-free survival (DFS) among patients who achieved an R0 resection was 52% (95% CI, 23%–81%), and the median OS was 4.8 years (95% CI, 3.303–6.362).[16,17] Lorenz et al reported the outcome of neoadjuvant FOLFOX in 42 patients with resectable liver metastases. The phase II part of the study had two arms, in which patients were assigned to 3 or 6 cycles of FOLFOX. The ORR was 48%, and 36 of the patients (86%) underwent surgical resection. R0 resection was achieved in 31 patients (74%).[18]

FOLFIRI

In several smaller studies, irinotecan chemotherapy doublets have been explored as preoperative systemic therapy in potentially curable metastatic colorectal cancer, as an alternative to oxaliplatin. In a phase II study of 35 patients with hepatic metastases considered resectable upon presentation, Bathe et al evaluated the benefits of neoadjuvant folinic acid, 5-FU, and irinotecan (FOLFIRI). The ORR was 40%. All 30 patients who proceeded to surgery achieved an R0 resection. The median DFS for all resected patients was 23 months from the time of liver tumor resection, and the 2-year OS was 93%.[19]

In a study of 40 patients who presented with liver metastases deemed unresectable, Pozzo et al assessed FOLFIRI as a conversion therapy. They reported an ORR of 47.5%. All 13 patients (32.5%) who went to surgery had an R0 resection.[20] The median DFS in resected patients was 52.5 months, and the 5-year survival was 62%.[21] Ho et al reported similar results in 40 patients given a median of 12 cycles of FOLFIRI as conversion therapy. The ORR was 55% (95% CI, 39.5%–70.4%), but only 10% of the patients were able to undergo surgical resection.[22]

FOLFOXIRI

As a natural extension of the doublet therapies using oxaliplatin or irinotecan with fluoropyrimidines, Falcone et al explored the combination of all three drugs for conversion therapy. This phase III study demonstrated the efficacy of folinic acid, 5-FU, oxaliplatin, and irinotecan (FOLFOXIRI) vs FOLFIRI in unresectable liver metastases. The median number of cycles was 11 for FOLFOXIRI and 10 for FOLFIRI. The ORR was 60% vs 34%, favoring FOLFOXIRI (P < .0001), and the rate of R0 resection also favored FOLFOXIRI (15% vs 6%; P = .033).[23] Masi et al reported the follow-up results of three different trials for patients who underwent treatment with FOLFOXIRI for unresectable liver metastasis. The total number of patients was 196, and the median number of chemotherapy cycles was 11. The ORR was 70%, and R0 resection was achieved in 37 patients (19%). The 5-year survival in the R0 resection group was 42%.[24]

Antibody therapy

Beyond chemotherapy, preoperative antibody therapies have also been explored. Gruenberger et al assessed neoadjuvant CAPEOX combined with bevacizumab in 56 patients with metastatic colorectal cancer and resectable hepatic metastases. In this phase II trial, the median number of treatment cycles was 6. The ORR was 73.2%, and the R0 resection rate was 93%.[25] Wong et al assessed preoperative CAPEOX combined with bevacizumab in 46 patients with metastatic disease with both resectable and unresectable liver metastases. The phase II trial had an ORR of 78% (95% CI, 63%–89%). The rate of R0 resection was 20%, and 40% of unresectable metastases were converted to resectable.[26] Uetake et al reported that after 6 cycles of the combination of FOLFOX and bevacizumab, 19 patients with resectable disease had an ORR of 68.4% and 16 of these patients (84.2%) had an R0 resection. In the same study, 26 patients with unresectable disease had an ORR of 46.2% and 4 patients (15.4%) had R0 resections.[27] In a study by Bertolini et al, 21 patients with unresectable liver metastasis were given 6 cycles of FOLFOX combined with bevacizumab. The ORR was 57.1%. Thirteen patients (61.9%) achieved R0 resections. The progression-free survival (PFS) and the OS in the surgical group were 12.9 months and 22.5 months, respectively.[28] Recently, Gruenberger et al assessed the effect of combining bevacizumab with either FOLFOXIRI or FOLFOX in 80 patients with unresectable liver metastasis. The ORR was 81% vs 62%, favoring the FOLFOXIRI arm. For patients who underwent surgery, R0 resection was achieved in 20 (49%) and 9 (23%) patients, respectively, again favoring the FOLFOXIRI arm. The PFS was 18.6 months (95% CI, 12.9–22.3 months) and 11.5 months (95% CI, 9.6–13.6 months), favoring the FOLFOXIRI arm.[29] Masi et al evaluated the effect of combining preoperative FOLFOXIRI with bevacizumab in 57 patients with unresectable liver metastasis. The median number of cycles was 12. The ORR was 77%; 18 patients (32%) had surgery, and 15 (26%) achieved an R0 resection.[30]

The use of anti–epidermal growth factor receptor antibody therapy has also been explored. Primrose et al assessed the benefit of adding cetuximab to chemotherapy vs chemotherapy alone for resectable liver metastases in tumors that were KRAS wild-type at exon 2. The chemotherapy regimens were FOLFOX, FOLFIRI, and CAPEOX; cetuximab was the antibody used in those arms where included. Complete or partial tumor responses occurred in 73 of 117 patients (62%) receiving chemotherapy alone and in 83 of 119 patients (70%) receiving chemotherapy plus cetuximab. The ORR was 62% for patients receiving chemotherapy alone and 70% for patients receiving chemotherapy plus cetuximab (P = .59). The rate of R0 resection was 15% in both groups.[31] In a smaller study, Hatano et al assessed the addition of cetuximab to FOLFOX in 35 patients with unresectable liver metastases. The ORR was 77.3%, and the R0 resection rate was 50%.[32] Seven cycles of FOLFIRI combined with cetuximab in 23 patients with unresectable liver metastases resulted in an ORR of 39.1%. Although the rate of R0 resection was not reported, 7 patients (30.4%) had curative surgery.[33] Van Cutsem et al reported on the use of preoperative FOLFIRI with or without cetuximab in patients with unresectable liver metastasis and both KRAS-mutant and wild-type tumors. The ORRs were 57.3% and 39.7%, favoring the cetuximab arm for KRAS wild-type tumors. The rates of R0 resection were 7.9% and 4.6%, again favoring the cetuximab arm in KRAS wild-type tumors.[34,35] Saridaki et al demonstrated the effect of the preoperative combination of FOLFOXIRI and cetuximab in 30 patients with KRAS wild-type colon cancer and unresectable liver metastases; 24 patients (80%) had previous adjuvant therapy. The planned duration of preoperative therapy was 6 months. The ORR was 70%, and 11 patients (37%) achieved R0 resection.[36]

Cetuximab given with either FOLFOX or FOLFIRI has also been evaluated in patients with metastatic colorectal cancer and unresectable liver metastases. Folprecht et al retrospectively identified 64 patients whose tumors were KRAS and BRAF wild-type and showed an ORR of 72%. The rates of R0 resection were not reported for KRAS and BRAF wild-type subsets.[37,38] Ye et al assessed the addition of cetuximab to either FOLFOX or FOLFIRI as a conversion therapy for unresectable liver metastases in KRAS wild-type colorectal cancers. The ORR was 57.1% vs 29.4%, favoring the addition of cetuximab (P < .01). The rates of R0 resection were 25.7% vs 7.4%, also favoring the cetuximab arm (P < .01).[39,40] In a phase II trial, the efficacy of adding cetuximab to FOLFOX was assessed in patients with unresectable liver metastases and KRAS wild-type tumors.[41] Of the 73 patients enrolled, 46 completed 12 weeks of therapy. The ORR was 73%, and the rate of R0 resection was 27%. The median time to progression for those who had R0 resection was 14.1 months (95% CI, 1.3–30.8 months).[41] In a retrospective review of 151 patients with unresectable liver metastases who received cetuximab combined with irinotecan, oxaliplatin, or both, the ORR was 15.2% and the R0 resection rate was 9%.[42]

Adding panitumumab to CAPEOX in 49 patients with unresectable liver metastases produced an ORR of 65%. Surgery was performed in 21 of the patients (43%), and 14 (67%) had R0 resections.[43]

Discussion

In patients with stage IV colorectal cancer and a limited extent of metastatic disease, an upfront multidisciplinary discussion to consider the feasibility of resecting all metastases is required. This process and its timing are critical, since, based on the evidence we have summarized, the sequences of surgery and medical therapy should be quite different. No therapy or surgery should be undertaken until both medical and surgical providers have jointly discussed and agreed upon the plan of care.

The studies of preoperative medical therapy for the management of patients with metastatic disease that is deemed completely resectable at time of presentation, and thus curable, consistently suggest that there is no benefit to the use of upfront medical therapy in these patients. This remains so despite a number of different regimens used, including both chemo- and biologic therapies (again, as summarized in Table 1). Most of these studies were phase II studies and lacked a comparator arm in which the patients received upfront surgery. The single phase III study that compared neoadjuvant chemotherapy with upfront surgery did not demonstrate superiority with neoadjuvant chemotherapy.[37] Thus, our preferred treatment paradigm for these patients is to proceed directly to surgery, as would be the case with any lower stage of colon cancer. Medical therapy for the management of residual microscopic metastatic disease in these patients should be reserved for the postoperative setting, administered in a conventional adjuvant manner.

Conversely, for those patients who have a metastatic tumor burden deemed unresectable but potentially convertible to resectable if the burden were adequately reduced, the evidence does support the use of upfront medical therapy to achieve this conversion (as summarized in Table 2). Several regimens have been explored for conversion, and none has been shown to be clearly superior. However, in two phase III studies,[23,44] triplet chemotherapy with FOLFOXIRI achieved a better ORR, more frequent R0 margins of resection, and more surgical candidates than did treatment with a doublet of FOLFIRI. Therefore, for those patients whose performance status suggests that they would tolerate FOLFOXIRI, this is our preferred approach. While no studies have compared FOLFOXIRI/antibody therapy with FOLFOXIRI alone, Gruenberger, Masi, and their colleagues have demonstrated that the addition of bevacizumab is a feasible approach with good outcomes, and Saridaki and colleagues have demonstrated the same with cetuximab.[29,30,36] Barring a contraindication to the antibody, the addition of either bevacizumab or cetuximab to FOLFOXIRI is appropriate.

The administration of FOLFOXIRI is not universally feasible, given its highly toxic nature (adverse effects include marrow suppression, fatigue, and emetogenicity). While not all toxicity can be anticipated, the oncologist should consider whether the patient is likely to tolerate this regimen well enough to remain on the recommended dosage schedule. If not, an alternative chemotherapy doublet should be recommended. Since different studies have suggested better outcomes with either FOLFOX or FOLFIRI, we have no preference between the two as a standard paradigm and we select agents based on individual patient preference. This might include, for example, using FOLFOX in patients who prefer to avoid alopecia or who have baseline diarrheal symptoms, or using FOLFIRI in patients who have a baseline peripheral neuropathy. Even for those patients who cannot tolerate FOLFOXIRI, the addition of a biologic agent to the selected chemotherapy doublet is appropriate for incorporation in the conversion therapy.[26-28,30,32,33,35,37-39,41,43]

As with chemotherapy doublets, no clearly superior outcome has been described for an antibody class. Therefore, whether chemotherapy consists of FOLFOXIRI, FOLFOX, or FOLFIRI, we select an antibody again based on individual patient preference and anticipated tolerance. However, the lower cost and absence of skin toxicity often tend to favor bevacizumab over cetuximab or panitumumab.

Regardless of the regimen administered with intent of conversion to resectable disease, close monitoring of tumor response is essential in order to optimize timing of any surgery. As summarized in Table 2, there was a wide range in total number of cycles of therapy across the various trials. It is not appropriate to predetermine the number of cycles that should be used preoperatively. Rather, close monitoring of disease response should be undertaken, with repeat radiographic assessment and multidisciplinary consideration every 2 to 3 months. When it is agreed that maximal response has been achieved, based on this close interval monitoring, the multidisciplinary team should then consider whether surgery is feasible. Should the tumor response be inadequate for surgical attempt, there are no data to suggest that an alternative, second chemotherapeutic regimen is likely to achieve this outcome. If surgical resection is achieved, there is no strong evidence for an alternative adjuvant strategy beyond standard FOLFOX. Our usual approach is to recommend the standard 12 cycles of adjuvant FOLFOX therapy, with any chemotherapy that was administered neoadjuvantly omitted. While clinicians may elect to pursue another strategy (eg, use of other agents based on neoadjuvant tumor response, extended maintenance therapy with fluoropyrimidine monotherapy), it is imperative that the patient understand that there is not a strong level of evidence for such approaches and that the oncologist present the risks and benefits to the patient with an emphasis on the large extent of the unknown.

Future studies could conceivably establish a single best medical approach for the conversion of metastatic colorectal cancer to a resectable degree of disease, and moreover, that such an approach could offer benefit to patients in the neoadjuvant setting. However, given our increasing understanding of the diversity of colorectal cancer from patient to patient, it is much more likely that a variety of approaches will continue to be validated, with therapeutic recommendations relying on individual tumor characteristics and individual patient preferences and comorbid conditions. This variety again highlights how critical it is for a multidisciplinary team to synthesize treatment recommendations before commencing therapy or proceeding to surgery.

Financial Disclosure:Dr. Smaglo has financial arrangements with Taiho. Dr. Marshall has financial arrangements with Amgen, Bayer, Celgene, and Genentech. Dr. Al-Hajeili has no relevant disclosures.

References:

1. Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103:117-28.

2. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2012. National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2012/, based on November 2014 SEER data submission [posted to the SEER web site, April 2015]. Accessed December 22, 2015.

3. Ciliberto D, Prati U, Roveda L, et al. Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trials. Oncol Rep. 2012;27:1849-56.

4. Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol. 1997;15:938-46.

5. Rossi L, Zullo A, Zoratto F, et al. Chemotherapy and target therapy as neo-adjuvant approach for initially unresectable colorectal liver metastases. Oncol Rev. 2012;6:e6.

6. Joern F, Gunter H, Thomas J, et al. Outcome for stage II and III rectal and colon cancer equally good after treatment improvement over three decades. Int J Colorectal Dis. 2015;30:797-806.

7. Amri R, Bordeianou LG, Sylla P, Berger DL. Variations in metastasis site by primary location in colon cancer. J Gastrointest Surg. 2015;19:1522-7.

8. Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. Oncologist. 2008;13:51-64.

9. Kishi Y, Zorzi D, Contreras CM, et al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol. 2010;17:2870-6.

10. Kemeny N. Management of liver metastases from colorectal cancer. Oncology (Williston Park). 2006;20:1161-76, 1179; discussion 79-80, 85-6.

11. John SK, Robinson SM, Rehman S, et al. Prognostic factors and survival after resection of colorectal liver metastasis in the era of preoperative chemotherapy: an 11-year single-centre study. Dig Surg. 2013;30:293-301.

12. Tan MC, Butte JM, Gonen M, et al. Prognostic significance of early recurrence: a conditional survival analysis in patients with resected colorectal liver metastasis. HPB (Oxford). 2013;15:803-13.

13. Alberts SR, Horvath WL, Sternfeld WC, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005;23:9243-9.

14. Adam R, Avisar E, Ariche A, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal [liver] metastases. Ann Surg Oncol. 2001;8:347-53.

15. Coskun U, Buyukberber S, Yaman E, et al. Xelox (capecitabine plus oxaliplatin) as neoadjuvant chemotherapy of unresectable liver metastases in colorectal cancer patients. Neoplasma. 2008;55:65-70.

16. Wein A, Riedel C, Bruckl W, et al. Neoadjuvant treatment with weekly high-dose 5-fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer. Oncology. 2003;64:131-8.

17. Boxberger F, Albrecht H, Konturek PC, et al. Neoadjuvant treatment with weekly high-dose 5-fluorouracil as a 24h-infusion, folinic acid and biweekly oxaliplatin in patients with primary resectable liver metastases of colorectal cancer: long-term results of a phase II trial. Med Sci Monit. 2010;16:CR49-CR55.

18. Lorenz M, Staib-Sebler E, Gog C, et al. Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies. Zentralbl Chir. 2003;128:87-94.

19. Bathe OF, Ernst S, Sutherland FR, et al. A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases. BMC Cancer. 2009;9:156.

20. Pozzo C, Basso M, Cassano A, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol. 2004;15:933-9.

21. Barone C, Nuzzo G, Cassano A, et al. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer. 2007;97:1035-9.

22. Ho WM, Ma B, Mok T, et al. Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group. Med Oncol. 2005;22:303-12.

23. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25:1670-6.

24. Masi G, Loupakis F, Pollina L, et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg. 2009;249:420-5.

25. Gruenberger B, Tamandl D, Schueller J, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol. 2008;26:1830-5.

26. Wong R, Cunningham D, Barbachano Y, et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol. 2011;22:2042-8.

27. Uetake H, Yasuno M, Ishiguro M, et al. A multicenter phase II trial of mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808). Ann Surg Oncol. 2015;22:908-15.

28. Bertolini F, Malavasi N, Scarabelli L, et al. FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer. Br J Cancer. 2011;104:1079-84.

29. Gruenberger T, Bridgewater J, Chau I, et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol. 2015;26:702-8.

30. Masi G, Loupakis F, Salvatore L, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol. 2010;11:845-52.

31. Primrose J, Falk S, Finch-Jones M, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol. 2014;15:601-11.

32. Hatano E, Okuno M, Nakamura K, et al. Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-ras status for unresectable colorectal liver metastasis (BECK study). J Hepatobiliary Pancreat Sci. 2015;22:634-45.

33. Min BS, Kim NK, Ahn JB, et al. Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastases. Onkologie. 2007;30:637-43.

34. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408-17.

35. Van Cutsem E, Kohne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29:2011-9.

36. Saridaki Z, Androulakis N, Vardakis N, et al. A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial. Br J Cancer. 2012;107:1932-7.

37. Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11:38-47.

38. Folprecht G, Gruenberger T, Bechstein W, et al. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol. 2014;25:1018-25.

39. Ye LC, Liu TS, Ren L, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol. 2013;31:1931-8.

40. Ye LC, Wei Y, Zhu DX, et al. Impact of early tumor shrinkage on clinical outcome in wild-type-KRAS colorectal liver metastases treated with cetuximab. J Gastroenterol Hepatol. 2015;30:674-9.

41. Ji JH, Park SH, Lee J, et al. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis. Cancer Chemother Pharmacol. 2013;72:223-30.

42. Adam R, Aloia T, Levi F, et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol. 2007;25:4593-602.

43. Leone F, Artale S, Marino D, et al. Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The MetaPan study. Cancer. 2013;119:3429-35.

44. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371:1007-16.

45. Taieb J, Artru P, Paye F, et al. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study. J Clin Oncol. 2005;23:502-9.

46. Souglakos J, Androulakis N, Syrigos K, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer. 2006;94:798-805.